Ipilimumab: A First-in-Class T-Cell Potentiator for Metastatic Melanoma.

IF 1.2 Q3 DERMATOLOGY Journal of Skin Cancer Pub Date : 2013-01-01 Epub Date: 2013-04-21 DOI:10.1155/2013/423829
Bartosz Chmielowski
{"title":"Ipilimumab: A First-in-Class T-Cell Potentiator for Metastatic Melanoma.","authors":"Bartosz Chmielowski","doi":"10.1155/2013/423829","DOIUrl":null,"url":null,"abstract":"<p><p>Ipilimumab, a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody that potentiates antitumor T-cell responses, has demonstrated improved survival in previously treated and treatment-naïve patients with unresectable stage III/IV melanoma. Survival benefit has also been shown in diverse patient populations, including those with brain metastases. In 2011, ipilimumab (3 mg/kg every 3 weeks for 4 doses) was approved by the Food and Drug Administration for unresectable or metastatic melanoma. Ipilimumab can induce novel response patterns for which immune-related response criteria have been proposed. irAEs are common but are usually low grade; higher grades can be severe and life-threatening. irAEs are usually manageable using established guidelines emphasizing vigilance and prompt intervention. This agent provides an additional therapeutic option in metastatic melanoma, and guidelines for management of adverse events facilitate clinical implementation of this new agent.</p>","PeriodicalId":17172,"journal":{"name":"Journal of Skin Cancer","volume":"2013 ","pages":"423829"},"PeriodicalIF":1.2000,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2013/423829","citationCount":"17","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Skin Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2013/423829","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2013/4/21 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 17

Abstract

Ipilimumab, a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody that potentiates antitumor T-cell responses, has demonstrated improved survival in previously treated and treatment-naïve patients with unresectable stage III/IV melanoma. Survival benefit has also been shown in diverse patient populations, including those with brain metastases. In 2011, ipilimumab (3 mg/kg every 3 weeks for 4 doses) was approved by the Food and Drug Administration for unresectable or metastatic melanoma. Ipilimumab can induce novel response patterns for which immune-related response criteria have been proposed. irAEs are common but are usually low grade; higher grades can be severe and life-threatening. irAEs are usually manageable using established guidelines emphasizing vigilance and prompt intervention. This agent provides an additional therapeutic option in metastatic melanoma, and guidelines for management of adverse events facilitate clinical implementation of this new agent.

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Ipilimumab:用于转移性黑色素瘤的一流t细胞增强剂。
Ipilimumab是一种全人类抗细胞毒性t淋巴细胞抗原-4单克隆抗体,可增强抗肿瘤t细胞反应,已证明可提高先前治疗和treatment-naïve不可切除的III/IV期黑色素瘤患者的生存率。在不同的患者群体中也显示出生存益处,包括脑转移患者。2011年,ipilimumab(每3周3mg /kg,共4次)被美国食品和药物管理局批准用于不可切除或转移性黑色素瘤。Ipilimumab可以诱导新的反应模式,免疫相关的反应标准已经提出。irae很常见,但通常等级较低;更高的分数可能会严重到危及生命。通过强调警惕和及时干预的既定指导方针,通常可以管理紧急事故。这种药物为转移性黑色素瘤提供了一种额外的治疗选择,不良事件管理指南促进了这种新药的临床应用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of Skin Cancer
Journal of Skin Cancer DERMATOLOGY-
CiteScore
2.30
自引率
18.20%
发文量
12
审稿时长
21 weeks
期刊介绍: Journal of Skin Cancer is a peer-reviewed, Open Access journal that publishes clinical and translational research on the detection, diagnosis, prevention, and treatment of skin malignancies. The journal encourages the submission of original research articles, review articles, and clinical studies related to pathology, prognostic indicators and biomarkers, novel therapies, as well as drug sensitivity and resistance.
期刊最新文献
Nonmelanoma Skin Cancer in the Heart of the Middle East: Analysis of Mohs Micrographic Surgery Cases From a Tertiary Care Center in Lebanon. Analysis of the Stockholm Public Health Cohort: Exploring How Ultraviolet Radiation and Other Factors Associate with Skin Cancer. Beyond the Scalpel: Advancing Strategic Approaches and Targeted Therapies in Nonexcisable Melanomas. Knowledge, Attitude, and Practice toward Skin Cancer among Patients of Dermatology Clinics and Medical Students/General Practitioners. Indoor Tanning among Sexual and Gender Minority Adolescents and Adults: Results from the 2020 Pennsylvania LGBT Health Needs Assessment.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1